Method and composition for the treatment of inflammatory bowel disease

• US 6,319,899 B1
• Filed: 09/14/1999
• Issued: 11/20/2001
• Est. Priority Date: 09/17/1997
• Status: Expired due to Fees

• Current Assignee: Nemours Foundation
• Original Assignee: Nemours Foundation
• Inventors: Schwartz, Marshall Z.
• Primary Examiner(s): BORIN, MICHAEL L
• Application Number:
  US09/395,129
• Time in Patent Office: 798 Days
• Field of Search: 514/2, 514/12
• US Class Current: 424/85.4
• CPC Class Codes: A61K 38/1833 Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The present invention relates to a method and composition for treating a patient having a condition characterized as inflammatory bowel disease with an effective dose of HGF. Mucosal damage and histologic lesions are reduced by administering HGF to patients suffering from the same. HGF may be administered to the patient lumenally or systemically.

Claims

1. A method for treating a patient having a condition characterized as inflammatory bowel disease comprising reducing cytokine inflammatory mediator activity by administering a dose of HGF effective to reduce the gene expression of cytokine inflammatory mediators.

2. The method of claim 1 wherein a patient has a condition selected from the group consisting of Chronic Ulcerative Colitis, Crohn'"'"'s Disease, necrotizing enterocolitis, severe acute gastroenteritis, chronic gastroenteritis, cholera, chronic infections of the bowel, immunologic disorders affecting the small intestine, and immunodeficiency syndromes affecting the small intestine.

3. The method of claim 1 wherein the administration of HGF is performed systemically.

4. The method of claim 1 wherein the administration of HGF is performed lumenally.

5. The method of claim 1 wherein the effective dosage range of HGF is between about 30 μ

g/kg body weight/day to about 300 μ

g/kg body weight/day.

6. The method of claim 1 wherein the effective dose of HGF is about 150 μ

g/kg body weight/day.

7. The method of claim 1 wherein the cytokine inflammatory mediators are selected from the group consisting of TNF-α

, INF-γ

, and combinations thereof.

8. The method of claim 1 wherein the reduction of gene expression of cytokine inflammatory mediators results in a reduction in inflammation in the small bowel and colon.